Serving the Society Since 1986
高级搜索
Volume 33 Issue 2
April 2018

    Hewei Zhang, Mingqi Xia, Wei Wang, Decai Ju, Long Cao, Bai Wu, Xin Wang, Ying Wu, Ni Song, Jiaxin Hu, Changxiao Tian, Shucheng Zhang and Hua Wu. An Attenuated Highly Pathogenic Chinese PRRS Viral Vaccine Confers Cross Protection to Pigs against Challenge with the Emerging PRRSV NADC30-Like Strain[J]. Virologica Sinica, 2018, 33(2): 153-161. doi: 10.1007/s12250-018-0027-0
    Citation: Hewei Zhang, Mingqi Xia, Wei Wang, Decai Ju, Long Cao, Bai Wu, Xin Wang, Ying Wu, Ni Song, Jiaxin Hu, Changxiao Tian, Shucheng Zhang, Hua Wu. An Attenuated Highly Pathogenic Chinese PRRS Viral Vaccine Confers Cross Protection to Pigs against Challenge with the Emerging PRRSV NADC30-Like Strain .VIROLOGICA SINICA, 2018, 33(2) : 153-161.  http://dx.doi.org/10.1007/s12250-018-0027-0
    shu

    PRRSV TJM F92疫苗株对PRRSV NADC30-like分离株有相应的交叉保护作用

    • 1.

      华威特（北京）生物科技有限公司

    • 2.

      中国农业科学院特产研究所

    • 通讯作者： 武华, wuhuasinovetah@gmail.com, ORCID: 0000-0003-3198-8149
    • 收稿日期： 2017-10-10
      录用日期： 2018-01-30
      出版日期： 2018-03-29
    • 本实验室于河南某地分离出一株PRRSV毒株，该分离株与NADC30-like毒株有相同的分子特征，将其命名为PRRSV HN201605分离株。本实验目的是研究PRRSV高致病性活疫苗TJM-F92对NADC30-like HN201605毒株有无交叉保护作用。25头PRRSV抗原抗体阴性2月龄猪随机被分为5组，Vac/ChA组，Unvac/ChA组，Vac/ChB组，Unvac/ChB组和对照组。Vac/ChA和Vac/ChB组猪通过肌肉途径免疫TJM-F92（105.0 TCID50/mL），1mL／头。免疫28天（攻毒0天）后，Vac/ChA和Unvac/ChA组猪通过滴鼻途径接种104.5TCID50/mL PRRSV TJ F3毒株，2mL/头；而Vac/ChB和Unvac/ChB组猪采用相同途径和剂量接种NADC30-like HN201605 F3毒株。结果显示，Vac/ChA和Vac/ChB组猪群均得到保护，未见相关临床症状；Unvac/ChA组猪群有明显的高热，病理变化，体重减轻等临床症状，Unvac/ChB组猪群临床症状较轻。结果表明NADC30-like HN201605分离株为中等致病性毒株，高致病性PRRSV疫苗株TJM-F92可以作为一种有效安全的候选疫苗应用于市场。

    An Attenuated Highly Pathogenic Chinese PRRS Viral Vaccine Confers Cross Protection to Pigs against Challenge with the Emerging PRRSV NADC30-Like Strain

    • 1.

      Sinovet (Beijing) Biotechnology Co., Ltd, Beijing 100085, China

    • 2.

      State Key Laboratory for Molecular Biology of Special Economic Animals, Institute of Special Economic Animal and Plant Sciences, Chinese Academy of Agricultural Sciences, Changchun 130112, China

    • Corresponding author: Hua Wu, wuhuasinovetah@gmail.com
    • ORCID: 0000-0003-3198-8149
    • Received Date: 10 October 2017
      Accepted Date: 30 January 2018
      Published Date: 29 March 2018
    • A novel PRRSV strain was isolated in China that was genetically similar to the NADC30 strain which is reported to have spread throughout China. The objective of the present study was to evaluate the cross-protective efficacy of the live vaccine TJM-F92 in young pigs against challenge with a NADC30-like strain, HN201605. Twenty-five PRRSV- and antibody-free pigs were randomly divided into the following five groups: Vac/ChA, Unvac/ChA, Vac/ChB, Unvac/ChB and the mock. The pigs in groups Vac/ChA and Vac/ChB were inoculated intramuscularly with 1 mL TJM-F92 (105.0 TCID50/mL). At 28 days post vaccination (0 days post challenge), groups Vac/ChA and Unvac/ChA were inoculated intranasally with 104.5 TCID50/mL PRRSV strain TJ F3 (2 mL/pig), while groups Vac/ChB and Unvac/ChB were inoculated, using the same route, with the same dose of the NADC30-like strain HN201605 F3. Protective effects of the PRRSV strain were observed in all pigs in the Vac/ChA and Vac/ChB groups. Neither high fever nor signs of clinical disease were observed through the experiment in these groups, whereas pigs in Unvac/ChA group exhibited serious clinical symptoms, pathological lesions, and weight loss. In Unvac/ChB group, pigs developed milder clinical symptoms, which demonstrated that the NADC30- like strain HN201605 had moderate pathogenicity. The results suggest that the MLV vaccine strain TJM-F92 is an effective and safe vaccine candidate for use in China.
    • 加载中

      1. Allende R, Lewis T, Lu Z, Rock D, Kutish G, Ali A, Doster A, Osorio F (1999) North American and European porcine reproductive and respiratory syndrome viruses differ in non-structural protein coding regions. J Gen Virol 80:307-315
          doi: 10.1099/0022-1317-80-2-307

      2. Bai X, Wang Y, Xu X, Sun Z, Xiao Y, Ji G, Li Y, Tan F, Li X, Tian K (2016) Commercial vaccines provide limited protection to NADC30-like PRRSV infection. Vaccine 34:5540-5545
          doi: 10.1016/j.vaccine.2016.09.048

      3. Brockmeier SL, Loving CL, Vorwald AC, Kehrli ME, Baker RB, Nicholson TL, Lager KM, Miller LC, Faaberg KS (2012) Genomic sequence and virulence comparison of four Type 2 porcine reproductive and respiratory syndrome virus strains. Virus Res 169:212-221
          doi: 10.1016/j.virusres.2012.07.030

      4. Calzada-Nova G, Husmann RJ, Schnitzlein WM, Zuckermann FA (2012) Effect of the host cell line on the vaccine efficacy of an attenuated porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 148:116-125
          doi: 10.1016/j.vetimm.2012.05.008

      5. Faaberg KS, Kehrli ME, Lager KM, Guo B, Han J (2010) In vivo growth of porcine reproductive and respiratory syndrome virus engineered nsp2 deletion mutants. Virus Res 154:77-85
          doi: 10.1016/j.virusres.2010.07.024

      6. Galliher-Beckley A, Li X, Bates JT, Madera R, Waters A, Nietfeld J, Henningson J, He D, Feng W, Chen R (2015) Pigs immunized with Chinese highly pathogenic PRRS virus modified live vaccine are protected from challenge with North American PRRSV strain NADC-20. Vaccine 33:3518-3525
          doi: 10.1016/j.vaccine.2015.05.058

      7. Halbur P, Miller L, Paul P, Meng X-J, Huffman E, Andrews J (1995a) Immunohistochemical identification of porcine reproductive and respiratory syndrome virus (PRRSV) antigen in the heart and lymphoid system of 3-week-old colostrum-deprived pigs. Vet Pathol 32:200-204
          doi: 10.1177/030098589503200218

      8. Halbur P, Paul P, Frey M, Landgraf J, Eernisse K, Meng X-J, Lum M, Andrews J, Rathje J (1995b) Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet Pathol 32:648-660
          doi: 10.1177/030098589503200606

      9. Halbur PG, Paul PS, Meng XJ, Lum MA, Andrews JJ, Rathje JA (1996) Comparative pathogenicity of nine US porcine reproductive and respiratory syndrome virus (PRRSV) isolates in a 5-week-old cesarean-derived, colostrum-deprived pig model. J Vet Diagn Invest 8:11-20
          doi: 10.1177/104063879600800103

      10. Holtkamp DJ, Kliebenstein JB, Neumann EJ, Zimmerman JJ, Rotto HF, Yoder TK, Wang C, Yeske PE, Mowrer CL, Haley CA (2013) Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. J Swine Health Prod 21:72-84

      11. Huang C, Zhang Q, W-h Feng (2015) Regulation and evasion of antiviral immune responses by porcine reproductive and respiratory syndrome virus. Virus Res 202:101-111
          doi: 10.1016/j.virusres.2014.12.014

      12. Kim DY, Kaiser TJ, Horlen K, Keith ML, Taylor LP, Jolie R, Calvert JG, Rowland RR (2009) Insertion and deletion in a non-essential region of the nonstructural protein 2 (nsp2) of porcine reproductive and respiratory syndrome (PRRS) virus: effects on virulence and immunogenicity. Virus Genes 38:118-128
          doi: 10.1007/s11262-008-0303-4

      13. Lager KM, Schlink SN, Brockmeier SL, Miller LC, Henningson JN, Kappes MA, Kehrli ME, Loving CL, Guo B, Swenson SL (2014) Efficacy of Type 2 PRRSV vaccine against Chinese and Vietnamese HP-PRRSV challenge in pigs. Vaccine 32:6457-6462
          doi: 10.1016/j.vaccine.2014.09.046

      14. Leng X, Li Z, Xia M, He Y, Wu H (2012a) Evaluation of the efficacy of an attenuated live vaccine against highly pathogenic porcine reproductive and respiratory syndrome virus in young pigs. Clin Vaccine Immunol 19:1199-1206
          doi: 10.1128/CVI.05646-11

      15. Leng X, Li Z, Xia M, Li X, Wang F, Wang W, Zhang X, Wu H (2012b) Mutations in the genome of the highly pathogenic porcine reproductive and respiratory syndrome virus potentially related to attenuation. Vet Microbiol 157:50-60
          doi: 10.1016/j.vetmic.2011.12.012

      16. Li X, Galliher-Beckley A, Huang H, Sun X, Shi J (2013) Peptide nanofiber hydrogel adjuvanted live virus vaccine enhances crossprotective immunity to porcine reproductive and respiratory syndrome virus. Vaccine 31:4508-4515
          doi: 10.1016/j.vaccine.2013.07.080

      17. Li C, Zhuang J, Wang J, Han L, Sun Z, Xiao Y, Ji G, Li Y, Tan F, Li X (2016a) Outbreak Investigation of NADC30-like PRRSV in South-East China. Transbound Emerg Dis 63:474-479
          doi: 10.1111/tbed.2016.63.issue-5

      18. Li Z, He Y, Xu X, Leng X, Li S, Wen Y, Wang F, Xia M, Cheng S, Wu H (2016b) Pathological and immunological characteristics of piglets infected experimentally with a HP-PRRSV TJ strain. BMC Vet Res 12:230
          doi: 10.1186/s12917-016-0854-x

      19. Liu C, Ning Y, Xu B, Gong W, Zhang D (2016) Analysis of genetic variation of porcine reproductive and respiratory syndrome virus (PRRSV) isolates in Central China. J Vet Med Sci 78:641-648 Mateu E, Diaz I (2008) The challenge of PRRS immunology. Vet J 177:345-351
          doi: 10.1292/jvms.15-0570

      20. Mengeling WL, Lager KM, Vorwald AC, Clouser DF (2003) Comparative safety and efficacy of attenuated single-strain and multi-strain vaccines for porcine reproductive and respiratory syndrome. Vet Microbiol 93:25-38
          doi: 10.1016/S0378-1135(02)00426-1

      21. Nelson EA, Christopher-Hennings J, Benfield DA (1994) Serum immune responses to the proteins of porcine reproductive and respiratory syndrome (PRRS) virus. J Vet Diagn Invest 6:410-415
          doi: 10.1177/104063879400600402

      22. Opriessnig T, Baker RB, Halbur PG (2007) Use of an experimental model to test the efficacy of planned exposure to live porcine reproductive and respiratory syndrome virus. Clin Vaccine Immunol 14:1572-1577
          doi: 10.1128/CVI.00332-07

      23. Park C, Seo HW, Kang I, Jeong J, Choi K, Chae C (2014) A new modified live porcine reproductive and respiratory syndrome vaccine improves growth performance in pigs under field conditions. Clin Vaccine Immunol 21:1350-1356
          doi: 10.1128/CVI.00377-14

      24. Renukaradhya GJ, Meng X-J, Calvert JG, Roof M, Lager KM (2015) Live porcine reproductive and respiratory syndrome virus vaccines: current status and future direction. Vaccine 33:4069-4080
          doi: 10.1016/j.vaccine.2015.06.092

      25. Roof M, Vaughn E, Burkhart K, Faaberg K (2003) Efficacy of modified live virus porcine reproductive and respiratory virus vaccines against heterologous respiratory challenge. In: Proceedings—4th international symposium on emerging and reemerging pig diseases, Rome, pp 117-118

      26. Sun Z, Wang J, Bai X, Ji G, Yan H, Li Y, Wang Y, Tan F, Xiao Y, Li X (2016) Pathogenicity comparison between highly pathogenic and NADC30-like porcine reproductive and respiratory syndrome virus. Arch Virol 161:2257-2261
          doi: 10.1007/s00705-016-2883-y

      27. Tian K, Yu X, Zhao T, Feng Y, Cao Z, Wang C, Hu Y, Chen X, Hu D, Tian X (2007) Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS ONE 2:e526
          doi: 10.1371/journal.pone.0000526

      28. Tian ZJ, An TQ, Zhou YJ, Peng JM, Hu SP, Wei TC, Jiang YF, Xiao Y, Tong GZ (2009) An attenuated live vaccine based on highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) protects piglets against HP-PRRS. Vet Microbiol 138:34-40
          doi: 10.1016/j.vetmic.2009.03.003

      29. Wei Z, Zhang J, Zhuang J, Sun Z, Gao F, Yuan S (2013) Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSV JX143. Vaccine 31:2062-2066
          doi: 10.1016/j.vaccine.2013.02.012

      30. Zhang C, Guo L, Jia X, Wang T, Wang J, Sun Z, Wang L, Li X, Tan F, Tian K (2015) Construction of a triple gene-deleted Chinese Pseudorabies virus variant and its efficacy study as a vaccine candidate on suckling piglets. Vaccine 33:2432-2437
          doi: 10.1016/j.vaccine.2015.03.094

      31. Zhang Q, Jiang P, Song Z, Lv L, Li L, Bai J (2016) Pathogenicity and antigenicity of a novel NADC30-like strain of porcine reproductive and respiratory syndrome virus emerged in China. Vet Microbiol 197:93-101
          doi: 10.1016/j.vetmic.2016.11.010

      32. Zhao K, Ye C, Chang XB, Jiang CG, Wang SJ, Cai XH, Tong GZ, Tian ZJ, Shi M, An TQ (2015) Importation and recombination are responsible for the latest emergence of highly pathogenic porcine reproductive and respiratory syndrome virus in China. J Virol 89:10712-10716
          doi: 10.1128/JVI.01446-15

      33. Zhou YJ, Hao XF, Tian ZJ, Tong GZ, Yoo D, An TQ, Zhou T, Li GX, Qiu HJ, Wei TC (2008) Highly virulent porcine reproductive and respiratory syndrome virus emerged in China. Transbound Emerg Dis 55:152-164
          doi: 10.1111/j.1865-1682.2008.01020.x

      34. Zhou L, Wang Z, Ding Y, Ge X, Guo X, Yang H (2015) NADC30-like strain of porcine reproductive and respiratory syndrome virus, China. Emerg Infect Dis 21:2256
          doi: 10.3201/eid2112.150360

      35. Zhou J, Li S, Wang X, Zou M, Gao S (2017) Bartha-k61 vaccine protects growing pigs against challenge with an emerging variant pseudorabies virus. Vaccine 35:1161-1166
          doi: 10.1016/j.vaccine.2017.01.003

    • 加载中
    • 10.1007s12250-018-0027-0.pdf

    Figures(8) / Tables(1)

    PDF

    Article Metrics

    Article views(6352) PDF downloads(26) Cited by(0)

    Related
    Proportional views
      通讯作者: 陈斌, bchen63@163.com
      • 1. 

        沈阳化工大学材料科学与工程学院 沈阳 110142

      1. 本站搜索
      2. 百度学术搜索
      3. 万方数据库搜索
      4. CNKI搜索

      An Attenuated Highly Pathogenic Chinese PRRS Viral Vaccine Confers Cross Protection to Pigs against Challenge with the Emerging PRRSV NADC30-Like Strain

        Corresponding author: Hua Wu, wuhuasinovetah@gmail.com
      • 1. Sinovet (Beijing) Biotechnology Co., Ltd, Beijing 100085, China
      • 2. State Key Laboratory for Molecular Biology of Special Economic Animals, Institute of Special Economic Animal and Plant Sciences, Chinese Academy of Agricultural Sciences, Changchun 130112, China
      • Received Date: 10 October 2017
      • Accepted Date: 30 January 2018
      • Published Date: 29 March 2018

      Abstract: A novel PRRSV strain was isolated in China that was genetically similar to the NADC30 strain which is reported to have spread throughout China. The objective of the present study was to evaluate the cross-protective efficacy of the live vaccine TJM-F92 in young pigs against challenge with a NADC30-like strain, HN201605. Twenty-five PRRSV- and antibody-free pigs were randomly divided into the following five groups: Vac/ChA, Unvac/ChA, Vac/ChB, Unvac/ChB and the mock. The pigs in groups Vac/ChA and Vac/ChB were inoculated intramuscularly with 1 mL TJM-F92 (105.0 TCID50/mL). At 28 days post vaccination (0 days post challenge), groups Vac/ChA and Unvac/ChA were inoculated intranasally with 104.5 TCID50/mL PRRSV strain TJ F3 (2 mL/pig), while groups Vac/ChB and Unvac/ChB were inoculated, using the same route, with the same dose of the NADC30-like strain HN201605 F3. Protective effects of the PRRSV strain were observed in all pigs in the Vac/ChA and Vac/ChB groups. Neither high fever nor signs of clinical disease were observed through the experiment in these groups, whereas pigs in Unvac/ChA group exhibited serious clinical symptoms, pathological lesions, and weight loss. In Unvac/ChB group, pigs developed milder clinical symptoms, which demonstrated that the NADC30- like strain HN201605 had moderate pathogenicity. The results suggest that the MLV vaccine strain TJM-F92 is an effective and safe vaccine candidate for use in China.

        HTML

      Introduction